pembrolizumab
merck
['melanoma', 'pembro']
striking difference in efs in favor to neoadjuvant pembro compared to adjuvant in pts with resectable stage iii/iv melanoma - practice changing results #esmo22 
Dermatologist | Attending Physician Dermato-Oncology, Skin Cancer Unit, University Hospital of Zurich | MD PhD Candidate Clinical Science UZH